NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
NGM Biopharmaceuticals, Inc
Stephen A Harrison; Mary E Rinella; Manal F Abdelmalek; James F Trotter; Angelo H Paredes; Hays L Arnold; Marcelo Kugelmas; Mustafa R Bashir; Mark J Jaros; Lei Ling; Stephen J Rossi; Alex M DePaoli; Rohit Loomba